Additionally, a case report showed that a patient with SQSTM1-NTRK1 fusion-positive advanced lung adenocarcinoma was treated with entrectinib, then developed partial response and had a complete remission of all brain metastases (41). Here, NTRK1 is linked to lung adenocarcinoma.